Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
NOVATO, Calif., Dec. 02, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer, will be presenting at the Oppenheimer 26th Annual Healthcare Conference on Wednesday, December 9, 2015 at 8:35am ET in New York.
The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc. Investors & Media Ryan Martins 844-758-7273
